CD4 and melanoma: A very recent report of melanoma treatment-related immune monitoring showed that PD-1 downregulation on CD4+CD25+CD127−PD1+ regulatory T lymphocytes under PD-1 inhibitor treatment was observed only in patients with favorable prognosis but not in patients with unfavorable prognosis [25].